Skip to main content

Table 1 Characteristics of all vaccinated patients

From: The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey

Pt Gender Age (y) Country Disease Disease activity Biological Other DMARDs Vaccination Adverse events Flare
1 Female 7 USA sJIA Inactive Anakinra 4 mg/kg/day Prednisone (0.12 mg/kg/day) Methotrexate Leflunomide Thalidomide Varicella zoster (booster) Varicella zoster infection
2 Female 1 Turkey sJIA Inactive Canakinumab 4 mg/kg/2 months Prednisone (5 mg/day) Methotrexate MMR booster Pneumonia Yes
3 Male 2 Turkey sJIA Inactive Tocilizumab 12 mg/kg/monthly Prednisone (2.5 mg/day) Oral polio vaccine Diarrhea
4 Male 12 USA MKD Inactive Anakinraa 100 mg/day (STOP 3-4D-1D) Varicella zoster (booster) Yes
5 Male 9 USA MKD Inactive Anakinraa 150 mg during flare (STOP 2D-1D) Varicella zoster (booster) Yes
6 Female 4 USA MKD Partially active Canakinumaba 4 mg/kg/6 weeks (STOP 3 M–3 M)   Varicella zoster (first vaccine) and MMR first vaccine Yes
7 Female 2 Turkey FMF Inactive Canakinumab 4 mg/kg/monthly Prednisone (2.5 mg/day) Colchicine MMR booster Yes
8 Female 9 Netherlands sJIA Inactive Anakinraa 1.7 mg/kg/2 days (STOP 2D-3D) Methotrexate MMR booster Yes
9 Male 3 Netherlands sJIA Inactive Tocilizumab 132 mg/14 days) Prednisone (2.5 mg/day) Varicella zoster (first vaccine) Yes
10 Male 12 Italy CAPS Inactive Anakinraa 1.5 mg/kg/day (STOP 3D-14D) Methylprednisolone (0.06 mg/kg/day) MMR booster
11 Female 12 Italy MKD Partially active Anakinraa 1.4 mg/kg/day (STOP 3D-28D) MMR booster
12 Female 9 Netherlands sJIA Inactive Anakinra 40 mg/3 days MMR booster
13 Male 9 Netherlands sJIA Inactive Tocilizumab 8 mg/kg/2 weeks Methotrexate MMR booster
14 Female 58 United Kingdom CAPS Inactive Anakinraa 100 mg/day (STOP 3D-3D) Yellow fever (first vaccine)
15 Female 28 United Kingdom CAPS Inactive Anakinraa 100 mg/day (STOP 3D-3D) Yellow fever (first vaccine)
16 Female 26 United Kingdom CAPS Inactive Anakinraa 100 mg/day (STOP 3D-3D) Yellow fever (first vaccine)
17 Female 44 United Kingdom CAPS Inactive Canakinumab (150 mg/2 months) Yellow fever (first vaccine)
  1. aBiological stopped prior to vaccination and restarted after vaccination. The period of discontinuation before and after vaccination is indicated in brackets.
  2. D days before or after vaccination, M months before or after vaccination